Education
About Us
Working with TipRanks
Follow Us
Whitehawk Therapeutics, Inc. (WHWK)
:WHWK
Top Page
Whitehawk Therapeutics
(NASDAQ:WHWK)
Rating:54Neutral
Price Target:
$1.50
▼( -24.62% Downside)
Positive Factors
Financial Transactions
The company has now completed divestiture of Aadi Subsidiary to Kaken for $102MM on top of closing a $100MM PIPE.
Preclinical Progress
Whitehawk continues to make solid preclinical progress on its portfolio of next-gen ADCs as it aims for INDs for all 3 by mid-2026, and these could be differentiated.
Negative Factors
Earnings
Whitehawk reported a net loss of $0.67 per share for 4Q24, significantly higher than previously estimated.
Expenses
Research and development expenses and selling, general, and administrative expenses greatly exceeded earlier estimates.
Whitehawk Therapeutics (WHWK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$82.91M
Dividend YieldN/A
Average Volume (3M)147.01K
Price to Earnings (P/E)13.3
Beta (1Y)0.41
Revenue Growth16.51%
EPS GrowthN/A
CountryUS
Employees40
SectorHealthcare
Sector Strength44
IndustryBiotechnology
Share Statistics
EPS (TTM)1.83
Shares Outstanding47,109,295
10 Day Avg. Volume70,987
30 Day Avg. Volume147,015
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit-1.84
Enterprise Value/Ebitda-0.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
Whitehawk Therapeutics Business Overview & Revenue Model
Company DescriptionWhitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
How the Company Makes Money
Whitehawk Therapeutics Financial Statement Overview
Summary
Whitehawk Therapeutics shows consistent revenue growth with a stable equity position but faces significant profitability challenges. The income statement highlights negative profit margins, and the balance sheet reflects substantial liabilities. Cash flow issues persist with negative free cash flow, though financing mitigates immediate liquidity risks.Income Statement
The company's income statement reveals consistent revenue growth over the years, but profitability remains a significant issue. Gross and net profit margins are negative, indicating high operational costs relative to revenue. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and challenges in reaching profitability. Despite revenue growth, the persistent net losses and high operating expenses present financial risks.45
Neutral
Balance Sheet
The balance sheet reflects a relatively strong equity position with a positive equity ratio. However, the company carries substantial liabilities, which, coupled with negative equity in earlier years, pose long-term risks. The debt-to-equity ratio is low, suggesting manageable debt levels. Nonetheless, the negative return on equity due to recurring net losses remains a concern.40
Negative
Cash Flow
Cash flow analysis shows significant operating cash outflows, consistent with the company's lack of profitability. However, the company has maintained negative free cash flow, which could strain liquidity in the absence of financing. The operating cash flow to net income ratio is unfavorable, indicating cash flow challenges. Despite these issues, the company has managed to maintain cash reserves through financing activities, mitigating immediate liquidity risks.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 25.98M | 24.35M | 15.22M | 1.00M | 14.00M | Gross Profit |
| -28.07M | 21.55M | 13.88M | 724.00K | 13.82M | EBIT |
| -67.46M | -71.93M | -58.96M | -111.22M | -2.55M | EBITDA |
| -64.63M | -65.36M | -60.12M | -109.15M | -2.48M | Net Income Common Stockholders |
| -63.69M | -65.77M | -57.01M | -110.09M | -3.48M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 47.24M | 108.84M | 172.56M | 148.99M | 4.46M | Total Assets |
| 70.32M | 132.42M | 184.24M | 157.91M | 18.82M | Total Debt |
| 833.00K | 1.27M | 1.66M | 605.00K | 10.26M | Net Debt |
| -27.84M | -61.62M | -37.36M | -148.38M | 5.80M | Total Liabilities |
| 17.84M | 27.23M | 25.86M | 21.50M | 31.26M | Stockholders Equity |
| 52.48M | 105.19M | 158.38M | 136.41M | -12.43M |
| Cash Flow | Free Cash Flow | |||
| -61.20M | -63.63M | -50.08M | -22.47M | -12.70M | Operating Cash Flow |
| -59.55M | -59.66M | -49.64M | -22.42M | -12.70M | Investing Cash Flow |
| 25.20M | 83.21M | -132.89M | 25.15M | -19.02K | Financing Cash Flow |
| 130.00K | 326.00K | 72.62M | 141.80M | 1.19M |
Whitehawk Therapeutics Technical Analysis
Positive
1.99
Price Trends
1.73
Positive
2.28
Negative
2.14
Negative
Market Momentum
0.04
Negative
63.72
Neutral
69.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WHWK, the sentiment is Positive. The current price of 1.99 is above the 20-day moving average (MA) of 1.65, above the 50-day MA of 1.73, and below the 200-day MA of 2.14, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 63.72 is Neutral, neither overbought nor oversold. The STOCH value of 69.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WHWK.
Whitehawk Therapeutics Risk Analysis
Whitehawk Therapeutics disclosed 101 risk factors in its most recent earnings report. Whitehawk Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. Q3, 2024
2.
We are a commercial-stage biopharmaceutical company, have a limited operating history and have a single product approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability. Q3, 2024
3.
We have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future. Q3, 2024
Whitehawk Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $82.91M | 13.27 | 17.69% | ― | 16.51% | ― | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
50 Neutral | $99.05M | ― | -60.25% | ― | 255.31% | -141.39% | |
45 Neutral | $74.74M | ― | -88.03% | ― | -21.28% | 36.26% | |
43 Neutral | $72.52M | ― | -456.32% | ― | ― | 0.13% | |
36 Underperform | $77.45M | ― | -76.21% | ― | ― | 23.55% | |
33 Underperform | $123.39M | 32.90 | 4.14% | ― | ― | 33.97% |
* Healthcare Sector Average
Performance Comparison
WHWK
Whitehawk Therapeutics
1.92
-0.01
-0.52%
VERU
Veru
0.49
-0.88
-64.23%
MGNX
MacroGenics
1.49
-3.21
-68.30%
BDTX
Black Diamond Therapeutics
2.03
-3.01
-59.72%
SRZN
Surrozen
7.31
-3.24
-30.71%
TNYA
Tenaya Therapeutics
0.44
-3.98
-90.05%
Whitehawk Therapeutics Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q4-2024)
| % Change Since: 21.34%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant strategic transformations, a promising pipeline of ADC therapies, and strong financial positioning. However, there are concerns about increased R&D expenses and net losses, which are common in early biotech transitions.Q4-2024 Updates
Positive Updates
Transformation and Strategic Transactions
Whitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.
Advanced ADC Platform
Whitehawk is rapidly progressing a multi-asset portfolio of advanced ADC therapy, leveraging a platform with minimal off-target toxicity, greater stability, and higher therapeutic index compared to first-generation predecessors.
Financial Position
Ended 2024 with $47.2 million in cash and expect $170-$180 million after transactions, funding operations into 2028.
FYARRO Sales Growth
FYARRO net product sales were $7.2 million for Q4, representing 14% growth over the prior year quarter. Full-year sales were $26 million, an increase of 7% over 2023.
Negative Updates
Increased R&D Expenses
Research and development expenses for Q4 increased to $14.3 million compared to $12.8 million in the prior year quarter, primarily due to in-process R&D expenses related to the acquired ADC programs.
Net Loss
Net loss for the fourth quarter was $18.3 million compared to $16.3 million in the fourth quarter of 2023. Net loss for the year was $63.7 million compared to $65.8 million in the prior year.
Company Guidance
In the earnings call for the fourth quarter and full year 2024, Whitehawk Therapeutics provided guidance on their transformative shift from Aadi Biosciences to an ADC-focused company. The key metrics highlighted include a $100 million PIPE financing and the divestiture of FYARRO, which resulted in a financial position of $170 million to $180 million in cash and equivalents, expected to fund operations into 2028. The company reported FYARRO net product sales of $7.2 million for the fourth quarter, marking a 14% increase from the previous year, and $26 million for the full year, a 7% rise from 2023. Research and development expenses increased to $14.3 million for the quarter and $51 million for the year, primarily due to ADC program acquisitions. Whitehawk plans to file three Investigational New Drug (IND) applications within 15 months for their ADC candidates, targeting PTK7, MUC16, and SEZ6, with anticipated Phase 1 trials in several high-potential cancer indications.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.